A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Dr Emma Bolderson, from QUT's School of Biomedical Sciences, has received a $460,552 grant from the Ovarian Cancer Research ...

There is no national ovarian cancer screening programme as, according to the NHS, there is not a test that can reliably pick ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Polymer-coated nanoparticles loaded with therapeutic drugs show significant promise for cancer treatment, including ovarian ...